Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
The androgen receptor (AR) has been shown to be of potential prognostic importance in retrospective cohorts. We evaluated immunohistochemical AR expression on a tissue microarray of 673 core biopsies from primary breast cancer patients treated with neoadjuvant docetaxel/doxorubicin/cyclophosphamide...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2011-11, Vol.130 (2), p.477-487 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 487 |
|---|---|
| container_issue | 2 |
| container_start_page | 477 |
| container_title | Breast cancer research and treatment |
| container_volume | 130 |
| creator | Loibl, Sibylle Müller, Berit Maria von Minckwitz, Gunter Schwabe, Michael Roller, Marc Darb-Esfahani, Silvia Ataseven, Beyhan du Bois, Andreas Fissler-Eckhoff, Annette Gerber, Bernd Kulmer, Uwe Alles, Jens-Uwe Mehta, Keyur Denkert, Carsten |
| description | The androgen receptor (AR) has been shown to be of potential prognostic importance in retrospective cohorts. We evaluated immunohistochemical AR expression on a tissue microarray of 673 core biopsies from primary breast cancer patients treated with neoadjuvant docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy in the prospective GeparTrio phase-III trial. AR was detected in 53.2% of tumours. Lowest AR expression was detected in triple-negative breast cancers (TNBC) with 21.2%. Highest AR expression was observed in Luminal A-like tumours with 67%. In AR-positive tumours, pathological complete response (pCR) rate was 12.8% compared to 25.4% in AR-negative tumours (
P
|
| doi_str_mv | 10.1007/s10549-011-1715-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_903660192</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A356142832</galeid><sourcerecordid>A356142832</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-a3b29192c1b57226c200f5843d70ccfcb1d3a8aa9246576d1af65ba21cfc081d3</originalsourceid><addsrcrecordid>eNp1ks9u1DAQxiMEokvhAbggCwScUmwnsZ3jquKfVIkLnK2JM9n1KmsvtrPQp-CVcZqFUgTywdLMb74Ze76ieMroBaNUvomMNnVbUsZKJllTqnvFijWyKiVn8n6xokzIUigqzopHMe4opa2k7cPijDNVyVq2q-LH2vXBb9CRgAYPyQeC3w8BY7TeEevIIdg9hGvSBYSYiAFnMBBwPbEp5iz21iR7xJvQIUs5H5M15AjjhDcCkCy6zKaskLAn32zaEoce-t10BJc1t7j3aYsBDtePiwcDjBGfnO7z4su7t58vP5RXn95_vFxflaZuVSqh6njLWm5Y10jOheGUDo2qq15SYwbTsb4CBdDyWjRS9AwG0XTAWc5RlZPnxetFN4_8dcKY9N5Gg-MIebIp6pZWQtDcIZPP_yJ3fgouD6dVq6SivKoz9GKBNjCitm7wKYCZJfW6agSruapmqYt_UPn0uLfGOxxsjt8pePVHwRZhTNvoxynl5cS7IFtAE3yMAQd92ptmVM9e0YtXdPaKnr2iVa55dnrY1O2x_13xyxwZeHkCIBoYh5B3b-MtVwuumJqF-MLFnHIbDLc_9P_uPwF3Htcc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>898780234</pqid></control><display><type>article</type><title>Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Loibl, Sibylle ; Müller, Berit Maria ; von Minckwitz, Gunter ; Schwabe, Michael ; Roller, Marc ; Darb-Esfahani, Silvia ; Ataseven, Beyhan ; du Bois, Andreas ; Fissler-Eckhoff, Annette ; Gerber, Bernd ; Kulmer, Uwe ; Alles, Jens-Uwe ; Mehta, Keyur ; Denkert, Carsten</creator><creatorcontrib>Loibl, Sibylle ; Müller, Berit Maria ; von Minckwitz, Gunter ; Schwabe, Michael ; Roller, Marc ; Darb-Esfahani, Silvia ; Ataseven, Beyhan ; du Bois, Andreas ; Fissler-Eckhoff, Annette ; Gerber, Bernd ; Kulmer, Uwe ; Alles, Jens-Uwe ; Mehta, Keyur ; Denkert, Carsten</creatorcontrib><description>The androgen receptor (AR) has been shown to be of potential prognostic importance in retrospective cohorts. We evaluated immunohistochemical AR expression on a tissue microarray of 673 core biopsies from primary breast cancer patients treated with neoadjuvant docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy in the prospective GeparTrio phase-III trial. AR was detected in 53.2% of tumours. Lowest AR expression was detected in triple-negative breast cancers (TNBC) with 21.2%. Highest AR expression was observed in Luminal A-like tumours with 67%. In AR-positive tumours, pathological complete response (pCR) rate was 12.8% compared to 25.4% in AR-negative tumours (
P
< 0.0001). In multivariate analysis, AR independently predicted pCR (OR 1.86; 95% CI [1.16–2.79]
P
= 0.0086). Overall patients with an AR-positive tumour had a significant better disease-free (DFS) (AR-positive 78.9% vs. AR-negative 72.5%; log-rank
P
= 0.0329) and overall survival (OS) (88.8% vs. 82.7%; log-rank
P
= 0.0234) than those with AR-negative tumours. Stratified analysis revealed that in the TNBC subgroup, but not in the other subgroups defined by ER, PgR and HER2, AR expression predicted a better DFS (AR-positive 85.7% vs. AR-negative 65.5% log-rank
P
= 0.0544) and OS (95.2% vs. 76.2%; log-rank
P
= 0.0355). Within the non-pCR subgroup, AR positivity selected a group with a significant better DFS (
P
= 0.045) and OS (0.021) but not within the pCR group. Patients with an AR-negative tumour have a higher chance of achieving a pCR than those with an AR-positive one. But, patients with AR-positive tumours have a better survival especially if they did not achieve a pCR.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-011-1715-8</identifier><identifier>PMID: 21837479</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adjuvant treatment ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomarkers ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer ; Cancer patients ; Cancer research ; Cancer therapies ; Carcinoma, Ductal, Breast - drug therapy ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - mortality ; Carcinoma, Ductal, Breast - pathology ; Carcinoma, Lobular - drug therapy ; Carcinoma, Lobular - metabolism ; Carcinoma, Lobular - mortality ; Carcinoma, Lobular - pathology ; Chemotherapy ; Clinical Trial ; Clinical Trials, Phase III as Topic ; Comparative analysis ; Cyclophosphamide - administration & dosage ; Disease-Free Survival ; Doxorubicin - administration & dosage ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Mammary gland diseases ; Medical prognosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate Analysis ; Neoadjuvant Therapy ; Oncology ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Randomized Controlled Trials as Topic ; Receptors, Androgen - metabolism ; Taxoids - administration & dosage ; Tumors</subject><ispartof>Breast cancer research and treatment, 2011-11, Vol.130 (2), p.477-487</ispartof><rights>Springer Science+Business Media, LLC. 2011</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-a3b29192c1b57226c200f5843d70ccfcb1d3a8aa9246576d1af65ba21cfc081d3</citedby><cites>FETCH-LOGICAL-c498t-a3b29192c1b57226c200f5843d70ccfcb1d3a8aa9246576d1af65ba21cfc081d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-011-1715-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-011-1715-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24628188$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21837479$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Loibl, Sibylle</creatorcontrib><creatorcontrib>Müller, Berit Maria</creatorcontrib><creatorcontrib>von Minckwitz, Gunter</creatorcontrib><creatorcontrib>Schwabe, Michael</creatorcontrib><creatorcontrib>Roller, Marc</creatorcontrib><creatorcontrib>Darb-Esfahani, Silvia</creatorcontrib><creatorcontrib>Ataseven, Beyhan</creatorcontrib><creatorcontrib>du Bois, Andreas</creatorcontrib><creatorcontrib>Fissler-Eckhoff, Annette</creatorcontrib><creatorcontrib>Gerber, Bernd</creatorcontrib><creatorcontrib>Kulmer, Uwe</creatorcontrib><creatorcontrib>Alles, Jens-Uwe</creatorcontrib><creatorcontrib>Mehta, Keyur</creatorcontrib><creatorcontrib>Denkert, Carsten</creatorcontrib><title>Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>The androgen receptor (AR) has been shown to be of potential prognostic importance in retrospective cohorts. We evaluated immunohistochemical AR expression on a tissue microarray of 673 core biopsies from primary breast cancer patients treated with neoadjuvant docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy in the prospective GeparTrio phase-III trial. AR was detected in 53.2% of tumours. Lowest AR expression was detected in triple-negative breast cancers (TNBC) with 21.2%. Highest AR expression was observed in Luminal A-like tumours with 67%. In AR-positive tumours, pathological complete response (pCR) rate was 12.8% compared to 25.4% in AR-negative tumours (
P
< 0.0001). In multivariate analysis, AR independently predicted pCR (OR 1.86; 95% CI [1.16–2.79]
P
= 0.0086). Overall patients with an AR-positive tumour had a significant better disease-free (DFS) (AR-positive 78.9% vs. AR-negative 72.5%; log-rank
P
= 0.0329) and overall survival (OS) (88.8% vs. 82.7%; log-rank
P
= 0.0234) than those with AR-negative tumours. Stratified analysis revealed that in the TNBC subgroup, but not in the other subgroups defined by ER, PgR and HER2, AR expression predicted a better DFS (AR-positive 85.7% vs. AR-negative 65.5% log-rank
P
= 0.0544) and OS (95.2% vs. 76.2%; log-rank
P
= 0.0355). Within the non-pCR subgroup, AR positivity selected a group with a significant better DFS (
P
= 0.045) and OS (0.021) but not within the pCR group. Patients with an AR-negative tumour have a higher chance of achieving a pCR than those with an AR-positive one. But, patients with AR-positive tumours have a better survival especially if they did not achieve a pCR.</description><subject>Adjuvant treatment</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Carcinoma, Ductal, Breast - drug therapy</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - mortality</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Carcinoma, Lobular - drug therapy</subject><subject>Carcinoma, Lobular - metabolism</subject><subject>Carcinoma, Lobular - mortality</subject><subject>Carcinoma, Lobular - pathology</subject><subject>Chemotherapy</subject><subject>Clinical Trial</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Comparative analysis</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kaplan-Meier Estimate</subject><subject>Mammary gland diseases</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoadjuvant Therapy</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Receptors, Androgen - metabolism</subject><subject>Taxoids - administration & dosage</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1ks9u1DAQxiMEokvhAbggCwScUmwnsZ3jquKfVIkLnK2JM9n1KmsvtrPQp-CVcZqFUgTywdLMb74Ze76ieMroBaNUvomMNnVbUsZKJllTqnvFijWyKiVn8n6xokzIUigqzopHMe4opa2k7cPijDNVyVq2q-LH2vXBb9CRgAYPyQeC3w8BY7TeEevIIdg9hGvSBYSYiAFnMBBwPbEp5iz21iR7xJvQIUs5H5M15AjjhDcCkCy6zKaskLAn32zaEoce-t10BJc1t7j3aYsBDtePiwcDjBGfnO7z4su7t58vP5RXn95_vFxflaZuVSqh6njLWm5Y10jOheGUDo2qq15SYwbTsb4CBdDyWjRS9AwG0XTAWc5RlZPnxetFN4_8dcKY9N5Gg-MIebIp6pZWQtDcIZPP_yJ3fgouD6dVq6SivKoz9GKBNjCitm7wKYCZJfW6agSruapmqYt_UPn0uLfGOxxsjt8pePVHwRZhTNvoxynl5cS7IFtAE3yMAQd92ptmVM9e0YtXdPaKnr2iVa55dnrY1O2x_13xyxwZeHkCIBoYh5B3b-MtVwuumJqF-MLFnHIbDLc_9P_uPwF3Htcc</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Loibl, Sibylle</creator><creator>Müller, Berit Maria</creator><creator>von Minckwitz, Gunter</creator><creator>Schwabe, Michael</creator><creator>Roller, Marc</creator><creator>Darb-Esfahani, Silvia</creator><creator>Ataseven, Beyhan</creator><creator>du Bois, Andreas</creator><creator>Fissler-Eckhoff, Annette</creator><creator>Gerber, Bernd</creator><creator>Kulmer, Uwe</creator><creator>Alles, Jens-Uwe</creator><creator>Mehta, Keyur</creator><creator>Denkert, Carsten</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20111101</creationdate><title>Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy</title><author>Loibl, Sibylle ; Müller, Berit Maria ; von Minckwitz, Gunter ; Schwabe, Michael ; Roller, Marc ; Darb-Esfahani, Silvia ; Ataseven, Beyhan ; du Bois, Andreas ; Fissler-Eckhoff, Annette ; Gerber, Bernd ; Kulmer, Uwe ; Alles, Jens-Uwe ; Mehta, Keyur ; Denkert, Carsten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-a3b29192c1b57226c200f5843d70ccfcb1d3a8aa9246576d1af65ba21cfc081d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adjuvant treatment</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Carcinoma, Ductal, Breast - drug therapy</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - mortality</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Carcinoma, Lobular - drug therapy</topic><topic>Carcinoma, Lobular - metabolism</topic><topic>Carcinoma, Lobular - mortality</topic><topic>Carcinoma, Lobular - pathology</topic><topic>Chemotherapy</topic><topic>Clinical Trial</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Comparative analysis</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kaplan-Meier Estimate</topic><topic>Mammary gland diseases</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoadjuvant Therapy</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Receptors, Androgen - metabolism</topic><topic>Taxoids - administration & dosage</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Loibl, Sibylle</creatorcontrib><creatorcontrib>Müller, Berit Maria</creatorcontrib><creatorcontrib>von Minckwitz, Gunter</creatorcontrib><creatorcontrib>Schwabe, Michael</creatorcontrib><creatorcontrib>Roller, Marc</creatorcontrib><creatorcontrib>Darb-Esfahani, Silvia</creatorcontrib><creatorcontrib>Ataseven, Beyhan</creatorcontrib><creatorcontrib>du Bois, Andreas</creatorcontrib><creatorcontrib>Fissler-Eckhoff, Annette</creatorcontrib><creatorcontrib>Gerber, Bernd</creatorcontrib><creatorcontrib>Kulmer, Uwe</creatorcontrib><creatorcontrib>Alles, Jens-Uwe</creatorcontrib><creatorcontrib>Mehta, Keyur</creatorcontrib><creatorcontrib>Denkert, Carsten</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loibl, Sibylle</au><au>Müller, Berit Maria</au><au>von Minckwitz, Gunter</au><au>Schwabe, Michael</au><au>Roller, Marc</au><au>Darb-Esfahani, Silvia</au><au>Ataseven, Beyhan</au><au>du Bois, Andreas</au><au>Fissler-Eckhoff, Annette</au><au>Gerber, Bernd</au><au>Kulmer, Uwe</au><au>Alles, Jens-Uwe</au><au>Mehta, Keyur</au><au>Denkert, Carsten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>130</volume><issue>2</issue><spage>477</spage><epage>487</epage><pages>477-487</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>The androgen receptor (AR) has been shown to be of potential prognostic importance in retrospective cohorts. We evaluated immunohistochemical AR expression on a tissue microarray of 673 core biopsies from primary breast cancer patients treated with neoadjuvant docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy in the prospective GeparTrio phase-III trial. AR was detected in 53.2% of tumours. Lowest AR expression was detected in triple-negative breast cancers (TNBC) with 21.2%. Highest AR expression was observed in Luminal A-like tumours with 67%. In AR-positive tumours, pathological complete response (pCR) rate was 12.8% compared to 25.4% in AR-negative tumours (
P
< 0.0001). In multivariate analysis, AR independently predicted pCR (OR 1.86; 95% CI [1.16–2.79]
P
= 0.0086). Overall patients with an AR-positive tumour had a significant better disease-free (DFS) (AR-positive 78.9% vs. AR-negative 72.5%; log-rank
P
= 0.0329) and overall survival (OS) (88.8% vs. 82.7%; log-rank
P
= 0.0234) than those with AR-negative tumours. Stratified analysis revealed that in the TNBC subgroup, but not in the other subgroups defined by ER, PgR and HER2, AR expression predicted a better DFS (AR-positive 85.7% vs. AR-negative 65.5% log-rank
P
= 0.0544) and OS (95.2% vs. 76.2%; log-rank
P
= 0.0355). Within the non-pCR subgroup, AR positivity selected a group with a significant better DFS (
P
= 0.045) and OS (0.021) but not within the pCR group. Patients with an AR-negative tumour have a higher chance of achieving a pCR than those with an AR-positive one. But, patients with AR-positive tumours have a better survival especially if they did not achieve a pCR.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>21837479</pmid><doi>10.1007/s10549-011-1715-8</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2011-11, Vol.130 (2), p.477-487 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_903660192 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adjuvant treatment Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomarkers Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer Cancer patients Cancer research Cancer therapies Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - mortality Carcinoma, Ductal, Breast - pathology Carcinoma, Lobular - drug therapy Carcinoma, Lobular - metabolism Carcinoma, Lobular - mortality Carcinoma, Lobular - pathology Chemotherapy Clinical Trial Clinical Trials, Phase III as Topic Comparative analysis Cyclophosphamide - administration & dosage Disease-Free Survival Doxorubicin - administration & dosage Female Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Kaplan-Meier Estimate Mammary gland diseases Medical prognosis Medical sciences Medicine Medicine & Public Health Middle Aged Multivariate Analysis Neoadjuvant Therapy Oncology Prognosis Proportional Hazards Models Prospective Studies Randomized Controlled Trials as Topic Receptors, Androgen - metabolism Taxoids - administration & dosage Tumors |
| title | Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A37%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Androgen%20receptor%20expression%20in%20primary%20breast%20cancer%20and%20its%20predictive%20and%20prognostic%20value%20in%20patients%20treated%20with%20neoadjuvant%20chemotherapy&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Loibl,%20Sibylle&rft.date=2011-11-01&rft.volume=130&rft.issue=2&rft.spage=477&rft.epage=487&rft.pages=477-487&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-011-1715-8&rft_dat=%3Cgale_proqu%3EA356142832%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=898780234&rft_id=info:pmid/21837479&rft_galeid=A356142832&rfr_iscdi=true |